2025 Q4 -tulosraportti
Vain PDF
47 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·44 min sittenWhat do we think about today's announcement, will this rise a lot now or will it be a bit limited as there are a few more days with warrants. Fantastic news but can it react as before because of warrants?
·3 min sittenI lean towards it closing in the green, but not that it will explode. The key is whether it manages to establish itself above 9.20–9.35. If it manages that with volume, it can quickly move towards 9.80–10.20. If, however, it fails around 9.00–9.20 and starts to slide, I think many short-term traders will sell, and then it could be pulled back towards 8.50–8.70, possibly all the way towards the warrant-strike 8.25.
50 min sitten50 min sittenCircio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy Circio´s proprietary circVec circular RNA platform has demonstrated up to 50-fold enhanced gene expression from AAV vectors in vivo GenAssist´s proprietary tissue-specific and liver de-targeting AAV capsids and promoters are designed for targeted delivery and expression in muscle and T-cells The objective is to evaluate the potential synergy of Circio´s and GenAssist’s complementary technologies to develop next generation AAVs to address major unmet medical needs in cancer and genetic muscle disease The collaboration is part of Circio´s partnering strategy to create next generation gene therapy vectors with improved performance and specificity, thereby solving a major challenge in gene therapy today Oslo, Norway, and Suzhou, China 1 June 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and GenAssist Ltd, a biotechnology company a pioneering next-generation genetic drug company against genetic diseases through its tissue‑specific AAV delivery platform, today jointly announce a research collaboration to develop circVec-enhanced AAV vectors specifically engineered for in vivo cell therapy and targeted, low dose systemic gene therapy. Genetic muscle disease is an area of major unmet medical need, where current gene therapy’s high dosing requirements are associated with severe toxicity. By integrating Circio´s and GenAssist´s complementary technologies, the parties aim to develop joint next generation of AAV gene therapy candidates. The focus is on addressing genetic muscle conditions where high and broad muscle-specific expression is required at substantially lower therapeutic AAV doses than can be achieved by conventional AAV gene therapy. "We are incredibly impressed by Circio’s unique circular RNA technology and see tremendous potential in how it can dramatically boost gene expression. Our second-generation AAV platform establishes a new benchmark for safety, utilizing highly tissue-specific, de-targeted capsids to dramatically lower systemic dosing while eliminating off-target toxicity," said Dr. Chunyan He, CEO of GenAssist. "Through our collaboration with Circio, we integrate their unique circular RNA technology—whose exceptional stability and superior transcriptional output ensure robust, sustained expression even at significantly reduced vector loads. This partnership directly addresses the core demands of next-generation genetic medicine, overcoming the traditional dose-expression trade-off to deliver safer and more effective therapies” In addition, Circio and GenAssist will explore the potential of generating joint in vivo CAR-T candidates for oncology and autoimmune applications. The collaboration will involve production of novel AAVs combining GenAssist´s proprietary T-cell targeting with the circVec expression cassette from Circio. The combined AAVs will subsequently be tested in vitro and in vivo, and if successful, candidates for further development will be nominated for pre-clinical development. “The targeted AAVs developed by GenAssist have the ability to specifically and efficiently transduce muscle or T-cells upon systemic delivery with near-complete liver de-targeting,” said Dr. Thomas B Hansen, CTO of Circio. “The partnership between Circio and GenAssist will aim to evaluate whether the enhanced circVec expression acts synergistically with these targeted capsids and promoters. This fits perfectly into Circio’s strategy of testing circVec in multiple tissues using different AAV variants, both internally and externally. This will allow us to identify new therapeutic avenues where circVec delivers a benefit, and forge partnerships potentially enabling multiple future development opportunities. China is a particularly interesting geography, with cutting edge science and accelerated pathways to establish early clinical data.”
·53 min sittenNew collaboration announced to the stock exchange today 🤩 https://newsweb.oslobors.no/message/674985
54 min sitten54 min sittenNew collaboration! ♥️🤩
·7 t sittenTomorrow I'm recording a podcast with Erik Digman Wiklund. The plan is a good and long conversation about companies, operations, and plans. A good way for all investors to get to know the company and the case. The episode will be published everywhere you listen and watch podcasts under Ett Case 🎧 Do you have any questions you want me to ask? 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
47 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·44 min sittenWhat do we think about today's announcement, will this rise a lot now or will it be a bit limited as there are a few more days with warrants. Fantastic news but can it react as before because of warrants?·3 min sittenI lean towards it closing in the green, but not that it will explode. The key is whether it manages to establish itself above 9.20–9.35. If it manages that with volume, it can quickly move towards 9.80–10.20. If, however, it fails around 9.00–9.20 and starts to slide, I think many short-term traders will sell, and then it could be pulled back towards 8.50–8.70, possibly all the way towards the warrant-strike 8.25.
- 50 min sitten50 min sittenCircio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy Circio´s proprietary circVec circular RNA platform has demonstrated up to 50-fold enhanced gene expression from AAV vectors in vivo GenAssist´s proprietary tissue-specific and liver de-targeting AAV capsids and promoters are designed for targeted delivery and expression in muscle and T-cells The objective is to evaluate the potential synergy of Circio´s and GenAssist’s complementary technologies to develop next generation AAVs to address major unmet medical needs in cancer and genetic muscle disease The collaboration is part of Circio´s partnering strategy to create next generation gene therapy vectors with improved performance and specificity, thereby solving a major challenge in gene therapy today Oslo, Norway, and Suzhou, China 1 June 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and GenAssist Ltd, a biotechnology company a pioneering next-generation genetic drug company against genetic diseases through its tissue‑specific AAV delivery platform, today jointly announce a research collaboration to develop circVec-enhanced AAV vectors specifically engineered for in vivo cell therapy and targeted, low dose systemic gene therapy. Genetic muscle disease is an area of major unmet medical need, where current gene therapy’s high dosing requirements are associated with severe toxicity. By integrating Circio´s and GenAssist´s complementary technologies, the parties aim to develop joint next generation of AAV gene therapy candidates. The focus is on addressing genetic muscle conditions where high and broad muscle-specific expression is required at substantially lower therapeutic AAV doses than can be achieved by conventional AAV gene therapy. "We are incredibly impressed by Circio’s unique circular RNA technology and see tremendous potential in how it can dramatically boost gene expression. Our second-generation AAV platform establishes a new benchmark for safety, utilizing highly tissue-specific, de-targeted capsids to dramatically lower systemic dosing while eliminating off-target toxicity," said Dr. Chunyan He, CEO of GenAssist. "Through our collaboration with Circio, we integrate their unique circular RNA technology—whose exceptional stability and superior transcriptional output ensure robust, sustained expression even at significantly reduced vector loads. This partnership directly addresses the core demands of next-generation genetic medicine, overcoming the traditional dose-expression trade-off to deliver safer and more effective therapies” In addition, Circio and GenAssist will explore the potential of generating joint in vivo CAR-T candidates for oncology and autoimmune applications. The collaboration will involve production of novel AAVs combining GenAssist´s proprietary T-cell targeting with the circVec expression cassette from Circio. The combined AAVs will subsequently be tested in vitro and in vivo, and if successful, candidates for further development will be nominated for pre-clinical development. “The targeted AAVs developed by GenAssist have the ability to specifically and efficiently transduce muscle or T-cells upon systemic delivery with near-complete liver de-targeting,” said Dr. Thomas B Hansen, CTO of Circio. “The partnership between Circio and GenAssist will aim to evaluate whether the enhanced circVec expression acts synergistically with these targeted capsids and promoters. This fits perfectly into Circio’s strategy of testing circVec in multiple tissues using different AAV variants, both internally and externally. This will allow us to identify new therapeutic avenues where circVec delivers a benefit, and forge partnerships potentially enabling multiple future development opportunities. China is a particularly interesting geography, with cutting edge science and accelerated pathways to establish early clinical data.”
- ·53 min sittenNew collaboration announced to the stock exchange today 🤩 https://newsweb.oslobors.no/message/674985
- 54 min sitten54 min sittenNew collaboration! ♥️🤩
- ·7 t sittenTomorrow I'm recording a podcast with Erik Digman Wiklund. The plan is a good and long conversation about companies, operations, and plans. A good way for all investors to get to know the company and the case. The episode will be published everywhere you listen and watch podcasts under Ett Case 🎧 Do you have any questions you want me to ask? 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
47 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·44 min sittenWhat do we think about today's announcement, will this rise a lot now or will it be a bit limited as there are a few more days with warrants. Fantastic news but can it react as before because of warrants?·3 min sittenI lean towards it closing in the green, but not that it will explode. The key is whether it manages to establish itself above 9.20–9.35. If it manages that with volume, it can quickly move towards 9.80–10.20. If, however, it fails around 9.00–9.20 and starts to slide, I think many short-term traders will sell, and then it could be pulled back towards 8.50–8.70, possibly all the way towards the warrant-strike 8.25.
- 50 min sitten50 min sittenCircio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy Circio´s proprietary circVec circular RNA platform has demonstrated up to 50-fold enhanced gene expression from AAV vectors in vivo GenAssist´s proprietary tissue-specific and liver de-targeting AAV capsids and promoters are designed for targeted delivery and expression in muscle and T-cells The objective is to evaluate the potential synergy of Circio´s and GenAssist’s complementary technologies to develop next generation AAVs to address major unmet medical needs in cancer and genetic muscle disease The collaboration is part of Circio´s partnering strategy to create next generation gene therapy vectors with improved performance and specificity, thereby solving a major challenge in gene therapy today Oslo, Norway, and Suzhou, China 1 June 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and GenAssist Ltd, a biotechnology company a pioneering next-generation genetic drug company against genetic diseases through its tissue‑specific AAV delivery platform, today jointly announce a research collaboration to develop circVec-enhanced AAV vectors specifically engineered for in vivo cell therapy and targeted, low dose systemic gene therapy. Genetic muscle disease is an area of major unmet medical need, where current gene therapy’s high dosing requirements are associated with severe toxicity. By integrating Circio´s and GenAssist´s complementary technologies, the parties aim to develop joint next generation of AAV gene therapy candidates. The focus is on addressing genetic muscle conditions where high and broad muscle-specific expression is required at substantially lower therapeutic AAV doses than can be achieved by conventional AAV gene therapy. "We are incredibly impressed by Circio’s unique circular RNA technology and see tremendous potential in how it can dramatically boost gene expression. Our second-generation AAV platform establishes a new benchmark for safety, utilizing highly tissue-specific, de-targeted capsids to dramatically lower systemic dosing while eliminating off-target toxicity," said Dr. Chunyan He, CEO of GenAssist. "Through our collaboration with Circio, we integrate their unique circular RNA technology—whose exceptional stability and superior transcriptional output ensure robust, sustained expression even at significantly reduced vector loads. This partnership directly addresses the core demands of next-generation genetic medicine, overcoming the traditional dose-expression trade-off to deliver safer and more effective therapies” In addition, Circio and GenAssist will explore the potential of generating joint in vivo CAR-T candidates for oncology and autoimmune applications. The collaboration will involve production of novel AAVs combining GenAssist´s proprietary T-cell targeting with the circVec expression cassette from Circio. The combined AAVs will subsequently be tested in vitro and in vivo, and if successful, candidates for further development will be nominated for pre-clinical development. “The targeted AAVs developed by GenAssist have the ability to specifically and efficiently transduce muscle or T-cells upon systemic delivery with near-complete liver de-targeting,” said Dr. Thomas B Hansen, CTO of Circio. “The partnership between Circio and GenAssist will aim to evaluate whether the enhanced circVec expression acts synergistically with these targeted capsids and promoters. This fits perfectly into Circio’s strategy of testing circVec in multiple tissues using different AAV variants, both internally and externally. This will allow us to identify new therapeutic avenues where circVec delivers a benefit, and forge partnerships potentially enabling multiple future development opportunities. China is a particularly interesting geography, with cutting edge science and accelerated pathways to establish early clinical data.”
- ·53 min sittenNew collaboration announced to the stock exchange today 🤩 https://newsweb.oslobors.no/message/674985
- 54 min sitten54 min sittenNew collaboration! ♥️🤩
- ·7 t sittenTomorrow I'm recording a podcast with Erik Digman Wiklund. The plan is a good and long conversation about companies, operations, and plans. A good way for all investors to get to know the company and the case. The episode will be published everywhere you listen and watch podcasts under Ett Case 🎧 Do you have any questions you want me to ask? 👇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt